Palmitoyl Pentapeptide-4 vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Palmitoyl Pentapeptide-4 and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Palmitoyl Pentapeptide-4 | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Palmitoyl Pentapeptide-4 (Matrixyl Original) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Mimics collagen breakdown products (matrikines) that signal fibroblasts to produce new collagen matrix components including types I, III, and IV collagen. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | 802.05 Da | 693 Da |
| Half-life | N/A (topical depot effect) | 8-12 hours (topical) |
| Bioavailability | Topical: ~8-12% penetration | Good (topical) |
| Typical dose | 2-8% in formulation | 2-4% in formulation |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical serum or cream | Topical |
Palmitoyl Pentapeptide-4 reported benefits
- Proven collagen stimulation
- Wrinkle depth reduction
- Improved skin firmness
- Well-tolerated
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.